Troikaa Pharma receives US patent for pain relief formula
MUMBAI: Ahmeadbad based Troikka Pharma on Wednesday said it has got a patent for Dynapar QPS, a novel pain relief formula. Troikaa Pharmaceuticals, a company with research focus on developing patented, said it had been administering clinical trial.
“Based on the positive results of a clinical trial (Clinical Trial Registry Number CTRI/2105/02/ 005510), DCGI approved Dynapar QPS as a treatment for pain in osteoarthritis is the only topical pain killer approved by DCGI for this condition. Additionally, Dynapar QPS is approved for all kinds of musculoskeletal pains like backache, neck pain, knee pain etc,” the company said in a statement Wednesday.
Also read: DCGI approves Nintedanib for the treatment of systemic sclerosis
Dynapar QPS
Dr Ketan R Patel, Chairman & Managing Director, Troikaa Pharmaceuticals Ltd said ”Dynapar QPS is a novel pain relief formula which provides quick powerful and long-lasting pain relief upon administration at the site of pain. Publications in scientific journals of repute confirm 5 times higher penetration of the pain killer Diclofenac through the skin as compared to the other topically used diclofenac formulations.”
The Department of Science & Technology (India) had recognised Dynapar QPS for the successful commercialisation of indigenous technology by rewarding it with TDB (Technology Development Board) National Award in the year 2015, the company statement added.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
